Article
[18F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [18F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine - 3 Jan 2025
Weeks Joanna K, Pantel Austin R, Gitto Sarah B, Liu Fang, Schubert Erin K, Pryma Daniel A, Farwell Michael D, Mankoff David A, Mach Robert H, Simpkins Fiona, Lin Lilie L
Abstract excerpt
Poly(adenosine diphosphate-ribose) polymerase-1 (PARP1) inhibitors have improved ovarian cancer treatment outcomes. However, clinical response remains heterogeneous. Existing biomarkers, mainly breast cancer susceptibility genes 1 and 2 (BRCA1/2), are suboptimal. New tools are needed to guide patient selection. In this study, [18F]fluorthanatrace ([18F]FTT), a PET radiotracer for imaging PARP1, was compared with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.